Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability.
about
Drug nanocrystals: A way toward scale-upPerformance Parameters and Characterizations of Nanocrystals: A Brief ReviewStability and in vivo evaluation of pullulan acetate as a drug nanocarrier.Nanosizing of a poorly soluble drug: technique optimization, factorial analysis, and pharmacokinetic study in healthy human volunteers.In situ loading of basic fibroblast growth factor within porous silica nanoparticles for a prolonged releasePathway of cytotoxicity induced by folic acid modified selenium nanoparticles in MCF-7 cells.Cyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation.A novel domperidone hydrogel: preparation, characterization, pharmacokinetic, and pharmacodynamic properties.Preparation, physical characterization and pharmacokinetic study of paclitaxel nanocrystals.Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112.Fabrication of isradipine nanosuspension by anti-solvent microprecipitation-high-pressure homogenization method for enhancing dissolution rate and oral bioavailability.Folate-mediated targeted and intracellular delivery of paclitaxel using a novel deoxycholic acid-O-carboxymethylated chitosan-folic acid micellesNanosuspensions: a promising drug delivery strategy.Accumulation and Toxicity of Superparamagnetic Iron Oxide Nanoparticles in Cells and Experimental Animals.Eudragit-based nanosuspension of poorly water-soluble drug: formulation and in vitro-in vivo evaluationNanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization.Manufacturing Techniques and Surface Engineering of Polymer Based Nanoparticles for Targeted Drug Delivery to Cancer.A mini review of nanosuspensions development.The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product.Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations.Development of a nanogel formulation for transdermal delivery of tenoxicam: a pharmacokinetic-pharmacodynamic modeling approach for quantitative prediction of skin absorption.A critical review about methodologies for the analysis of mucoadhesive properties of drug delivery systems.Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells.Chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery.Itraconazole nanosuspension for oral delivery: Formulation, characterization and in vitro comparison with marketed formulation.Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement.Enhanced intestinal absorption activity and hepatoprotective effect of herpetrione via preparation of nanosuspensions using pH-dependent dissolving-precipitating/homogenization process.Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: development, optimization and evaluation.Targeted Tumor Therapy Based on Nanodiamonds Decorated with Doxorubicin and Folic Acid.Nanosuspension Technologies for Delivery of Poorly Soluble Drugs
P2860
Q26744024-273547D8-55B5-4D73-B0BC-ABC4733FA411Q28077580-4A33D753-2E12-4890-8AD6-96F6D3B56545Q33605225-B18DC563-D32A-47CE-B820-055F74FC86B4Q33800631-4E37F571-D833-4411-8069-470100EF5709Q33949775-F607AD90-48B8-44F9-B249-C1B68C1F20A7Q34402275-A4D4F6F1-8A6F-464D-8AA4-61EC8A08B0BBQ34409932-8886BE45-1C52-4164-976D-6D56819EB041Q34730346-615CD462-7DEB-4A59-8F3E-E69C87F96020Q35231632-E2756393-1FD2-4145-9F15-EC88E3049B5CQ35284235-BCF3A305-7EFE-43C8-AD75-5188D6299958Q35580982-C21B4607-E6DA-4A06-8BD1-D868B28A26E9Q35694291-FD90A0D6-C88D-4A9A-81D1-DD0AD5E90642Q35826447-8DB1D3F4-2AA0-4E3B-ABC3-169B00A697ACQ36108983-36F8899E-3BF0-4334-8E0C-8A4CE7C76122Q36442159-A85C7185-BC20-4A1E-A054-B7FFD0D2F430Q36636492-E849FF1C-46B1-4AD2-AB44-0E688BDAA358Q37636197-0E9E7DF3-28B8-47E8-835A-791482342BB2Q37970772-2FF6E4FE-A522-49AD-AA08-D6D6715AB60EQ38239948-2E13082C-E7ED-4005-909A-2815072C3E0AQ38470559-8907BB8C-E5E6-40E6-8AFF-CAF0AB3C7BC0Q39136890-ADEAE225-56C9-4D9A-9DE8-3DB54DAD19F1Q39170252-6F1E23E2-FCBE-49C1-A5A7-BF80A9EEB4CDQ39789952-A460AA9B-7AD1-4E97-ADCC-B65603B03D56Q41122837-C538EB10-B646-444A-B0C2-FCC739045169Q42581340-EF7B8646-4F63-4CEC-91AC-14A4DE71CCB3Q46814392-A6E612CF-A3D3-493A-A0E3-120F0797CB23Q46837639-7021714C-BDD6-4208-B6E4-56F5110A7F90Q46901905-6D72A0A9-D6BB-4FD0-AD8D-8E9DAD60ED09Q48438566-AA3FD199-373F-42CE-AA7F-847AF8F75962Q51157262-18E740CF-F042-4E1A-BEAC-B1D4CC29024DQ59113220-A7F029A7-B5D4-41A4-9951-4CEE4AC4FC73
P2860
Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Buparvaquone mucoadhesive nano ...... ation and long-term stability.
@ast
Buparvaquone mucoadhesive nano ...... ation and long-term stability.
@en
type
label
Buparvaquone mucoadhesive nano ...... ation and long-term stability.
@ast
Buparvaquone mucoadhesive nano ...... ation and long-term stability.
@en
prefLabel
Buparvaquone mucoadhesive nano ...... ation and long-term stability.
@ast
Buparvaquone mucoadhesive nano ...... ation and long-term stability.
@en
P1476
Buparvaquone mucoadhesive nano ...... ation and long-term stability.
@en
P2093
P304
P356
10.1016/S0378-5173(02)00040-6
P407
P577
2002-04-01T00:00:00Z